Bladder Cancer Therapies | Antibody-Drug-Conjugate

This collection of documents focuses on advanced treatment modalities for bladder cancer, specifically emphasizing the role of antibody-drug conjugates like enfortumab vedotin and sacituzumab govitecan. Key topics include dosage protocols, safety measures, the significance of genomic testing for fgfr mutations, management of adverse effects, and insights into ongoing clinical trials. Additionally, it covers emerging therapies and innovative drug delivery methods that aim to enhance patient outcomes in bladder cancer treatment.

Precision Tactics With HER2-Targeting ADCs in HER2-Altered Solid Tumors: Candid Conversations and Clinical Consults

byPVI, PeerView Institute for Medical Education

Many Roads to Myeloma Remission: Making Sequential Choices With BCMA and Non-BCMA Immunotherapies

byPVI, PeerView Institute for Medical Education

Off-the-Shelf and on the Mark in NHL: Strategic Approaches With Bispecific Antibodies and ADCs

byPVI, PeerView Institute for Medical Education

Tailwinds of Innovation in SCLC: Exploring the Therapeutic Potential of ADCs

byPVI, PeerView Institute for Medical Education

Same Class, Different Agents: Practical Considerations for Managing Toxicities of Interest in Patients on TROP2-Directed Therapies in Breast Cancer

byPeerVoice

"Experts vs AI" ADC Challenge—Lung Cancer Edition: Interpreting the Evidence, Exploring Practicalities

byPVI, PeerView Institute for Medical Education

Applying Foresight to Optimise Emesis Control in Patients Receiving Antibody-Drug Conjugates

byPeerVoice

Staying at the Forefront of HER2 and TROP2-Directed Antibody-Drug Conjugate Advances in Breast Cancer

byPeerVoice

Practical Considerations for ADC-ICI Combinations in Advanced Urothelial Carcinoma: Identifying and Managing Adverse Events

byPeerVoice

Practical Protocols for Preventing and Managing Antibody-Drug Conjugate-Associated Nausea and Vomiting

byPeerVoice

A New Jigsaw Piece for Our Patient’s Puzzle: TROP2-Directed Therapy in HR+ Advanced Breast Cancer

byPeerVoice

Peer Pressure: How Well Do You Know Your ADCs? Cracking the Code of Targeted Delivery of Cytotoxic Payloads in Lung Cancer

byPVI, PeerView Institute for Medical Education

Making an Impact in Bladder Cancer Care: Integrating the Latest Evidence and Modern Therapeutic Advances Across the Disease Continuum

byPVI, PeerView Institute for Medical Education

Making an Impact in Bladder Cancer Care: Integrating the Latest Evidence and Modern Therapeutic Advances Across the Disease Continuum

byPVI, PeerView Institute for Medical Education

TROP2-Directed Antibody-Drug Conjugates for Breast Cancer: The Clinical Significance of the Construct

byPeerVoice

Abundance of Choice at First Line, Lack of Options Beyond: Addressing Unmet Needs in NSCLC Without Actionable Mutations

byPeerVoice

When HER2 Is Low or Negative: Emerging Evidence on Antibody-Drug Conjugates for Hormone Receptor-Positive and Triple-Negative Breast Cancers

byPeerVoice

Updates on HER3-Targeted Therapies in NSCLC and Breast Cancer

byPeerVoice

Clinical Case Challenge: Implementing ADCs Into Routine mTNBC Treatment Plans

byPeerVoice

Keeping to Target in mTNBC: Optimising Outcomes With Antibody-Drug Conjugates in Practice

byPeerVoice